Madrid

• Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to … Ended
  2022-501918-55-00 4 2023-09-12 Mild Alzheimer's disease
• Long-term extension study of ligelizumab in food allergy Ended
  2022-502366-25-00 5 2023-09-11 Food allergy
• A Study Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso‑O … Ended
  2022-502546-26-00 3 2023-09-11 Sickle Cell Disease
• A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal canc … Ended
  2023-503356-27-00 4 2023-09-07 Metastatic colorectal cancer that is resistant to the currently approv
• Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin Ended
  2023-506559-10-00 2 2023-09-07 Healthy volunteers
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Ended
  2023-503659-88-00 5 2023-09-05 Obesity
• A Phase 2b Study of MK-6024 in Adults with Precirrhotic Nonalcoholic Steatohepatitis Ended
  2022-502647-35-00 4 2023-09-01 Non-alcoholic steatohepatitis
• A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patie … Ended
  2022-502828-42-00 4 2023-09-01 Idiopathic Pulmonary Fibrosis
• A study to understand how well DC806 works and how safe it is in participants with plaque psoriasis Ended
  2022-502249-90-00 4 2023-08-31 Plaque Psoriasis
• Phase 3 Study Comparing Zimberelimab with Domvanalimab to Pembrolizumab in Advanced Non-Small Cell Lung Cancer Ended
  2022-503071-28-00 5 2023-08-31 Squamous Non-small cell Lung Cancer
• A Study of LY3437943 in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight (TRIUMPH-2) Ended
  2023-503658-11-00 5 2023-08-31 Type 2 Diabetes
• INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Stu … Ended
  2022-501661-47-00 4 2023-08-23 Myelofibrosis ; postlung transplant (BOS); chronic graft-versus-host d
• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
• A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat … Ended
  2022-501988-40-00 5 2023-08-17 RSV-associated (subtypes A and B) disease in adults aged 60 years of a
• RANDOMISED, CROSSOVER BIOEQUIVALENCE CLINICAL TRIAL OF APIXABAN 5 MG CAPSULES VS APIXABAN 5 MG FILM-COATED TABLETS, AFTER A SINGLE ORAL DOSE … Ended
  2023-506035-15-00 2 2023-08-16 thrombosis
• EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Met … Ended
  2024-515407-19-00 5 2023-08-16 Metastatic pancreatic ductal adenocarcinoma (mPDAC)
• A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary … Ended
  2022-500746-16-00 4 2023-08-11 Geographic Atrophy
• Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended
  2022-502000-73-00 5 2023-08-11 Focal Onset Seizures
• APTIVATE Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with … Ended
  2023-503244-14-00 7 2023-08-11 Relapsed or Refractory Acute Myeloid Leukemia (AML)
• A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i … Ended
  2023-508267-69-00 3 2023-08-11 Subjects with Aadvanced solid tumors for whom life-prolonging therapie
• A study evaluating the effects of GLPG3667 given as oral treatment for up to 24 weeks in adults with dermatomyositis Ended
  2022-501097-19-00 4 2023-08-09 dermatomyositis
• The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the tr … Ended
  2022-500449-26-00 6 2023-08-03 Type 2 diabetes mellitus (T2DM)
• A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase … Ended
  2022-502833-25-00 5 2023-08-02 Obesity
• A study of HFB200603 as a single agent and in combination with Tislelizumab in patients with advanced solid tumors Ended
  2022-502891-22-00 1 2023-08-02 Advanced Solid Tumors

Showing 2,929–2,952 of 3,550 trials